FDA OKs accelerated approval to twice-rejected Tudriqev with Opdivo for advanced melanoma
The FDA granted accelerated approval for vusolimogene oderparepvec-wtpg (Tudriqev, Replimune) combined with nivolumab (Opdivo) for adults with unresectable advanced cutaneous melanoma after progression on prior anti-PD-1 therapy. In the phase 1/2 IGNYTE trial (140 patients), the objective response rate was 24.2% with a median duration of response of 14.1 months. Confirmatory IGNYTE-3 is ongoing.
How this was made
The 30-second read
Why it matters
This is a regulatory milestone after two prior FDA rejections within 13 months, with the decision grounded in IGNYTE phase 1/2 efficacy (24.2% ORR, 14.1-month median DoR) and an ongoing confirmatory phase 3 trial (IGNYTE-3).
Market read
Traders can reprice regulatory probability and commercial optionality for Opdivo-based melanoma combinations following an FDA accelerated approval after prior rejection history.
What to watch
The article does not quantify safety beyond common adverse reactions or provide subgroup efficacy; traders may discount the commercial impact until IGNYTE-3 readout and real-world uptake data.
Background
The FDA approved vusolimogene oderparepvec-wtpg (Tudriqev, Replimune), an oncolytic immunotherapy previously called RP1, in combination with nivolumab (Opdivo) for unresectable advanced cutaneous melanoma after progression on prior anti-PD-1 therapy.
Ticker impact
FDA granted accelerated approval for vusolimogene oderparepvec-wtpg in combination with nivolumab (Opdivo), which is marketed by Bristol Myers Squibb.
Likely positive near-term sentiment for BMY tied to Opdivo label expansion, with follow-through dependent on confirmatory IGNYTE-3 results.
The article is a direct FDA regulatory milestone for an Opdivo combination, which typically supports incremental commercial expectations and reduces regulatory overhang versus prior rejections.
Market effects
Re-accelerates interest in oncolytic immunotherapy plus checkpoint inhibitor strategies for post anti-PD-1 advanced melanoma.
Primarily US regulatory catalyst, but can influence global oncology sentiment and trial partner expectations.
FDA label expansion can affect international adoption and competitive dynamics in advanced melanoma immunotherapy.
Counterpoint
Accelerated approvals can later be narrowed or withdrawn if confirmatory IGNYTE-3 fails to verify benefit, limiting long-term upside.
Key entities
- regulatorFDA
Granted accelerated approval for Tudriqev plus Opdivo in advanced melanoma after anti-PD-1 progression.
- drugTudriqev (vusolimogene oderparepvec-wtpg)
Oncolytic immunotherapy approved in combination with nivolumab for unresectable advanced cutaneous melanoma.
- drugOpdivo (nivolumab)
Checkpoint inhibitor used in the approved combination regimen.
- clinical_trialIGNYTE trial
Phase 1/2 study providing the efficacy data supporting accelerated approval; IGNYTE-3 is ongoing.
